Revolution Medicines, Inc. Q3 2026 Earnings Recap

The stock fell 11.0% after earnings, signaling investor disappointment despite the U.S. approval and European regulatory progress. The excerpt highlights ambitious expansion plans and early launch execution but provides no launch or financial metrics, leaving commercial uptake and the outlook unclear.

Key Takeaways

• The FDA approved RAS(ON)Q (daraxonrasib) for specified patients with metastatic pancreatic cancer on August 26; the company says U.S. prescriptions began immediately.
• The NCCN guidelines list RAS(ON)Q as a category 1 preferred subsequent therapy option in specified pancreatic cancer settings, including some beyond the FDA-approved indication.
• The EMA’s CHMP adopted a positive opinion for the drug in previously treated metastatic pancreatic cancer; European Commission approval is still pending.
• The FDA granted breakthrough therapy designation to investigational RAS(ON)Q plus chemotherapy in first-line metastatic pancreatic cancer and orphan drug designation to zoldonrasib for pancreatic cancer.
• The company is conducting four additional global Phase 3 pancreatic cancer studies, including trials of zoldonrasib plus chemotherapy and a RAS(ON) inhibitor doublet.